Published on February 26, 2026, this international study represents a major collaboration between The Life Raft Group and thirty-five leading cancer centers across the U.S., Europe, and Japan to better understand treatment for gastrointestinal stromal tumors (GIST) with KIT exon 9 mutations.
Survey highlights show that most GIST patients receive mutational testing, but awareness of ctDNA testing remains low despite strong interest.
Roadblocks to a cure - a review of first GISTT Summit 2024 in Essen, Germany by participant LRG Data Analyst Jerry Call.
ESMO 2024 Summary
The Life Raft Group is proud to share our ASCO Educational Book Manuscript - “Leveraging Patient Engagement Through Collaboration for Improved Global Health Outcomes in Sarcoma”
This summary article helps explain the results of Deciphera's Phase 3 INTRIGUE trial as published in Future Medicine, authored by Marina Symcox & Robin L Jones.
Dr. Ramesh Bulusu, Dr. John Glod & Dr. Jason Sicklick discussed GIST research updates and answered questions in this GIST Awareness Day 2023 presentation.
The LRG publishes, "Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry" Cancer Investigation ,Vol. 41, 2023. Issue 5 [...]
In this installment of Fueling GIST Research, our Data Management & Research team shares about their management & curation of the LRG GIST Patient Registry which informs patient direction, clinical trials, and research studies.
In this installment of Fueling GIST Research, Dr. César Serrano shares on the importance of GIST research & collaboration among institutions to build a vision of new treatments & a cure.
